At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 166 enrolled

Drug / intervention

BMS-986178 +5 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02737475

NCT02737475Phase 2Completed

Compare CT.gov

A Phase 1/2a Study of BMS-986178 Administered Alone or in Combination With Nivolumab and/or Ipilimumab in Subjects With Advanced Solid Tumors

Bristol-Myers Squibb·interventional·Posted Apr 14, 2016·Updated Jan 25, 2022

In Brief

A Phase 2 clinical trial evaluating BMS-986178, Nivolumab, and 4 other interventions for Advanced Cancer. Completed, enrolled 166 participants across 22 sites in 6 countries.

Detailed Summary

The purpose of the study is to determine the safety and tumor-shrinking ability of experimental medication BMS-986178, when given by itself or in combination with Nivolumab and/or Ipilimumab, in participants with solid cancers that are advanced or have spread.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsAdvanced Cancer

CountriesCanada, Israel, Italy, Netherlands, Spain, United States

Collaborators--

Timeline

Phase 2CompletedFinished

20162017201820192020202120222023202420252026

First PostedApr 2016

Enrollment StartJun 2016

Primary CompletionNov 2020

TodayJul 2026

First PostedApr 14, 2016

Enrollment StartJun 17, 2016

Primary CompletionNov 2, 2020

TodayJul 2, 2026

Enrollment to primary: 4.4 yearsPosted 10.2 years ago